We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.
- Authors
Schroth, Werner; Goetz, Matthew P; Hamann, Ute; Fasching, Peter A; Schmidt, Marcus; Winter, Stefan; Fritz, Peter; Simon, Wolfgang; Suman, Vera J; Ames, Matthew M; Safgren, Stephanie L; Kuffel, Mary J; Ulmer, Hans Ulrich; Boländer, Julia; Strick, Reiner; Beckmann, Matthias W; Koelbl, Heinz; Weinshilboum, Richard M; Ingle, James N; Eichelbaum, Michel; Schwab, Matthias; Brauch, Hiltrud
- Abstract
The growth inhibitory effect of tamoxifen, which is used for the treatment of hormone receptor-positive breast cancer, is mediated by its metabolites, 4-hydroxytamoxifen and endoxifen. The formation of active metabolites is catalyzed by the polymorphic cytochrome P450 2D6 (CYP2D6) enzyme.
- Publication
JAMA, 2009, Vol 302, Issue 13, p1429
- ISSN
1538-3598
- Publication type
Journal Article
- DOI
10.1001/jama.2009.1420